Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Cell Genesys (CEGE) -- Ignore unavailable to you. Want to Upgrade?

To: Secret_Agent_Man who wrote (814)	3/25/2000 5:38:00 PM
From: sam	Read Replies (1) \| Respond to of 1298

Some very interesting info regarding the adeno-associated viral (AAV) vector work being done now in hemophilia research using Cell Genesys' AAV gene delivery technology. Cell Genesys' AAV patent portfolio now includes more than 75 issued or granted patents and patent applications including a broad patent (U.S. Patent No. 5,753,500) issued in 1998 covering all gene therapy products that utilize AAV vectors to deliver genes. idealibrary.com